• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经母细胞瘤中 MYCN 扩增及 1p 缺失与高肿瘤血管生成的相关性

Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.

作者信息

Ozer Erdener, Altungoz Oguz, Unlu Mehtat, Aygun Nevim, Tumer Sait, Olgun Nur

机构信息

Departments of Pathology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

出版信息

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):181-6. doi: 10.1097/01.pai.0000210418.38246.58.

DOI:10.1097/01.pai.0000210418.38246.58
PMID:17525631
Abstract

The biologic behavior of neuroblastoma (NB) is extremely variable; therefore, the clinical behavior may be reliably predicted based on the analysis of a panel of prognostic parameters. High vascular density has been correlated with aggressive tumor progression in many types of cancers. The goal of this study was to correlate the tumor vascularity in NB with status of MYCN and the short arm of chromosome 1 (1p) to address the association between angiogenesis and genetic markers of prognostic significance. The study population consisted of 33 patients with histologically proven diagnosis of primary NB and no history of previous chemotherapy. Histologic quantitation of tumor angiogenesis was performed using 3 different methods: microvessel density, vascular grading, and Chalkley counting. MYCN amplification and 1p deletion were determined by using fluorescence in situ hybridization technique. The differentiation and mitosis-karyorrhexis index of tumor cells were also assessed using the Shimada System. MYCN amplification was present in 12 cases (36.3%), and 1p deletion in 16 (48.5%). Both genetic changes significantly correlated with increased tumor vascularity. In addition, tumor vascularity was significantly increased in tumors with high mitosis-karyorrhexis index or of undifferentiated histology. We conclude that angiogenesis shows close association with histologic and genetic prognosticators in NB. Our data support the validity of recent applications of antiangiogenic agents which interfere or block NB progression.

摘要

神经母细胞瘤(NB)的生物学行为极具变异性;因此,基于一组预后参数的分析可可靠地预测其临床行为。在许多类型的癌症中,高血管密度与肿瘤的侵袭性进展相关。本研究的目的是将NB中的肿瘤血管生成与MYCN状态及1号染色体短臂(1p)相关联,以探讨血管生成与具有预后意义的遗传标志物之间的关联。研究人群包括33例经组织学证实为原发性NB且无既往化疗史的患者。采用3种不同方法对肿瘤血管生成进行组织学定量:微血管密度、血管分级和Chalkley计数。使用荧光原位杂交技术确定MYCN扩增和1p缺失情况。还使用Shimada系统评估肿瘤细胞的分化和有丝分裂-核溶解指数。12例(36.3%)存在MYCN扩增,16例(48.5%)存在1p缺失。这两种基因改变均与肿瘤血管生成增加显著相关。此外,有丝分裂-核溶解指数高或组织学未分化的肿瘤中,肿瘤血管生成显著增加。我们得出结论,血管生成在NB中与组织学和基因预后因素密切相关。我们的数据支持近期应用抗血管生成药物干扰或阻断NB进展的有效性。

相似文献

1
Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.神经母细胞瘤中 MYCN 扩增及 1p 缺失与高肿瘤血管生成的相关性
Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):181-6. doi: 10.1097/01.pai.0000210418.38246.58.
2
Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.神经母细胞瘤中改良的岛田分类法与通过荧光原位杂交检测的MYCN和1p36状态的相关性
Cancer Genet Cytogenet. 2007 Jan 15;172(2):113-9. doi: 10.1016/j.cancergencyto.2006.10.005.
3
Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.用于快速同时测定治疗分层标志物MYCN扩增、1p缺失和11q缺失的定量实时PCR。
Diagn Mol Pathol. 2005 Sep;14(3):177-82. doi: 10.1097/01.pas.0000176767.10800.17.
4
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.对1号、2号、3号和11号染色体改变进行的荧光原位杂交(FISH)分析确定了神经母细胞瘤中的高危组。
Med Pediatr Oncol. 2003 Jul;41(1):30-5. doi: 10.1002/mpo.10313.
5
Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.具有不一致基因型-表型关系的神经母细胞瘤:4例MYCN扩增且组织学表现良好的病例报告。
Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.
6
Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.增大且明显的核仁可能提示MYCN扩增:一项关于神经母细胞瘤(低雪旺细胞基质)、未分化/低分化亚型且有高有丝分裂-核溶解指数的研究。
Cancer. 2005 Jan 1;103(1):174-80. doi: 10.1002/cncr.20717.
7
No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.没有证据表明在染色体亚带1p36.3内存在印记神经母细胞瘤抑制基因。
Cancer Res. 2002 Nov 15;62(22):6481-4.
8
Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.肿瘤内异质性MYCN扩增神经母细胞瘤与侵袭性基因谱神经母细胞瘤的比较遗传学研究。
Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.
9
The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.使用多重连接依赖探针扩增技术检测神经母细胞瘤预后分层的遗传参数
Genet Test Mol Biomarkers. 2016 Feb;20(2):74-80. doi: 10.1089/gtmb.2015.0165. Epub 2016 Jan 20.
10
[Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].[神经母细胞瘤患者2号染色体短臂遗传物质增加及1号染色体短臂缺失的检测方法及预后意义]
Vopr Onkol. 2013;59(5):591-8.

引用本文的文献

1
Dynamic Changes in Microvascular Density Can Predict Viable and Non-Viable Areas in High-Risk Neuroblastoma.微血管密度的动态变化可预测高危神经母细胞瘤中的存活和非存活区域。
Cancers (Basel). 2023 Feb 1;15(3):917. doi: 10.3390/cancers15030917.
2
Lymph microvascularization as a prognostic indicator in neuroblastoma.淋巴微血管生成作为神经母细胞瘤的预后指标
Oncotarget. 2018 May 25;9(40):26157-26170. doi: 10.18632/oncotarget.25457.
3
Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.血管模式为侵袭性神经母细胞瘤提供了治疗靶点。
Oncotarget. 2016 Apr 12;7(15):19935-47. doi: 10.18632/oncotarget.7661.
4
Neuroblastoma and MYCN.神经母细胞瘤与 MYCN
Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415.